Portal de Periódicos da CAPES

Yttrium-90-labelled somatostatin-analogue for cancer treatment

1998; Elsevier BV; Volume: 351; Issue: 9100 Linguagem: Inglês

10.1016/s0140-6736(05)78355-0

1474-547X

Andreas Otte, Jan Mueller‐Brand, Sophie Dellas, E. U. NITZSCHE, Richard Herrmann, H. R. MAECKE,

Neuroblastoma Research and Treatments

Treatment of unresectable somatostatin-receptor-positive tumours is difficult. 1 Lamberts SWJ van der Lely A-J de Herder WW Hofland LJ Octreotide. N Engl J Med. 1996; 334: 246-254 Crossref PubMed Scopus (895) Google Scholar , 2 Krenning EP Kooij PP Pauwels S et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion. 1996; 57: 57-61 Crossref PubMed Scopus (136) Google Scholar Chemotherapy and radiotherapy often fail. As an alternative, a new peptide vector, DOTA-D-Phe 1 Lamberts SWJ van der Lely A-J de Herder WW Hofland LJ Octreotide. N Engl J Med. 1996; 334: 246-254 Crossref PubMed Scopus (895) Google Scholar -Tyr 3 de Jong M Bakker WH Krenning EP et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, D-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997; 24: 368-371 Crossref PubMed Scopus (217) Google Scholar -Octreotide (DOTATOC; DOTA: 1,4,7,10-tetra-azacyclododecane-N,N′,N”,N”′-tetraacetic acid), that can be stably labelled with the β-emitting radioisotope yttrium-90, has been developed. 3 de Jong M Bakker WH Krenning EP et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, D-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997; 24: 368-371 Crossref PubMed Scopus (217) Google Scholar , 4 Otte A Jermann E Behe M et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med. 1997; 24: 792-795 PubMed Google Scholar We have treated ten patients with different somatostatin-receptor-positive tumours; six patients with multiple treatments and four with a single treatment. Each treatment was monitored by X-ray computed tomography (CT) and 111In-DOTATOC-scintigraphy. 18F-fluoro-deoxyglucose (FDG) positron emission tomography (PET) was done in two patients.